)
Visual
test
Novabay Pharmaceuticals
Novabay Pharmaceuticals (NBY) investor relations material
Novabay Pharmaceuticals Proxy Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy Filing summary30 Jan, 2026
Executive summary
Special Meeting scheduled for March 12, 2026, to vote on seven key proposals, including major stock issuances, charter amendments, and a new equity incentive plan.
Board unanimously recommends voting FOR all proposals, citing alignment with shareholder interests and future strategic flexibility.
Proposals address capital structure, governance, executive compensation, and compliance with NYSE American rules.
Voting matters and shareholder proposals
Proposal One: Approve issuance of 837,696,130 shares upon exercise of pre-funded warrants from January 2026 private placement.
Proposal Two: Approve issuance of 5,405,406 shares upon exercise of pre-funded warrants from October 2025 transaction.
Proposal Three: Amend charter to allow stockholder action by written consent.
Proposal Four: Amend charter for officer exculpation per Delaware law.
Proposal Five: Increase authorized common stock from 1.5B to 5B shares.
Proposal Six: Adopt 2026 Equity Incentive Plan, replacing 2017 plan.
Proposal Seven: Grant Board authority to adjourn the meeting to solicit more proxies if needed.
Board of directors and corporate governance
Board supports all proposals and encourages shareholder participation.
Charter amendments include removal of written consent prohibition and officer exculpation.
Board structure includes classified board with staggered three-year terms.
Nomination rights granted to major investors as part of private placement agreements.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6723
AI and industrial demand drive growth, timing business sold, inventory targets raised. - 032640
Net profit rose 61.9% on strong mobile and enterprise growth, with AIDC and AI driving expansion. - S68
Record revenue, robust margins, and strong IPO pipeline highlight broad-based growth. - 6417
Strong pachinko sales drove revenue growth, with major treasury stock cancellation planned. - BPT
H1 FY26 revenue hit $1B, with strong gas prices and LNG cargoes offsetting lower production. - CPAY
Record 2025 results and 2026 outlook driven by strong segment growth and capital deployment. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue.
Next Novabay Pharmaceuticals earnings date
Q4 202531 Mar, 2026
Novabay Pharmaceuticals
Next Novabay Pharmaceuticals earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
NovaBay Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative products for the eye care market. The company specializes in creating novel, fast-acting, synthetic anti-infectives designed to mimic the body’s natural defense mechanisms against infection. Its product portfolio includes solutions for eye care, such as Avenova, an antimicrobial lid and lash solution, as well as products for wound care and skincare. The company is headquartered in Emeryville, California, and its shares are listed on the NYSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage